Great opinion piece in Forbes by Juergen Eckhardt highlighting our CEO’s perspectives on first in class therapeutics!
Head of Leaps by Bayer and Head of Pharmaceuticals Business Development and Licensing. Executive Vice President, MD, MBA
Reflecting on my first Biotechnology Innovation Organization (BIO International conference), I was inspired by the level of interaction with business partners and the collective team spirit from our BD&L #teambayer during the event. I would like to thank Hanadie Yousef, John Wu, Aleksandra Rizo, and Seth Ettenberg for an informative discussion about Pioneering Paths, as they shared their experiences and research about bringing (current and past) first in class medicines to the market. I’ve also shared some reflections from #BIO24 in my latest Forbes article: Biotech Insiders Share Five Lessons From Pioneering New Medicines (forbes.com) What takeaways do you have from #BIO24?
